BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $265,878 | -16.1% | 7,045 | +1.3% | 0.01% | -11.1% |
| Q2 2023 | $316,870 | +23.6% | 6,955 | +10.0% | 0.01% | +12.5% |
| Q1 2023 | $256,420 | +60092.5% | 6,322 | -24.3% | 0.01% | -33.3% |
| Q4 2022 | $426 | -99.8% | 8,350 | +63.7% | 0.01% | +50.0% |
| Q3 2022 | $275,000 | -3.8% | 5,101 | +14.5% | 0.01% | -11.1% |
| Q2 2022 | $286,000 | +6.3% | 4,455 | +33.3% | 0.01% | +28.6% |
| Q3 2021 | $269,000 | +21.7% | 3,341 | +22.7% | 0.01% | -12.5% |
| Q1 2019 | $221,000 | -78.4% | 2,723 | -85.0% | 0.01% | -87.5% |
| Q4 2017 | $1,021,000 | -60.6% | 18,162 | -48.6% | 0.06% | -75.7% |
| Q4 2014 | $2,590,000 | +9.5% | 35,342 | +7.3% | 0.26% | +6.5% |
| Q3 2014 | $2,365,000 | +15.3% | 32,947 | +16.2% | 0.25% | +0.8% |
| Q2 2014 | $2,051,000 | +19.7% | 28,362 | +21.8% | 0.24% | +10.4% |
| Q1 2014 | $1,714,000 | +30.9% | 23,290 | +23.8% | 0.22% | +11.6% |
| Q4 2013 | $1,309,000 | +35.6% | 18,820 | +28.1% | 0.20% | -10.8% |
| Q3 2013 | $965,000 | +32.7% | 14,695 | +40.0% | 0.22% | +5.2% |
| Q2 2013 | $727,000 | – | 10,496 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |